Cell Permeable Cyclic Peptide Library Generation for Target-Based Screening

用于基于目标的筛选的细胞渗透性环肽库生成

• 批准号: 2440402
• 金额: --
• 依托单位: Newcastle University
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2440402
• 关键词: Cell; Permeable; Cyclic; Peptide; Library

Most drugs on the market are small molecules. Whilst these typically have good oral bioavailability, small molecule drugs do not always have a high selectivity for their targets. This can lead to increased toxicity from off-target effects. Likewise, small molecules are unable to selectively target proteins with large binding surfaces, such as those that are involved in protein-protein interactions. Large biologics such as proteins and antibodies exhibit very high selectivity for these targets but are not cell permeable and can thus only bind onto extracellular proteins. Furthermore, biologics are costly to manufacture compared to synthetic molecules. Peptides are promising therapeutics as they lie between the spectrum of small molecules and biologics whereby they have high selectivity for their targets, are able to probe a larger chemical space by targeting proteins with large binding surfaces and have relatively low production costs. However, the issue of low cell permeability, rapid metabolism and thus low oral bioavailability still persists for peptides and is a major limiting factor in their use as therapeutics.It has been observed that cyclisation of peptides has several structural benefits, such as eliminating the N- and C- termini to prevent proteolytic degradation, increasing rigidity and reducing the polar surface area to improve cell permeability and metabolic stability, leading to increased oral bioavailability.Over 1000 naturally occurring cyclic peptides have been discovered and some have been developed into widely used clinically available drugs, such as vancomycin, cyclosporin A and actinomycin D. However, the physicochemical properties underlying cyclic peptide cell permeability are unclear. The design of small molecule drugs is guided by Lipinski's Rule of 5 which defines the physicochemical properties that a drug should have to be orally bioavailable. Such rules include having a molecular weight <500, logP <5, number of hydrogen bond donors <5 and number of hydrogen bond acceptors <10. Due to the larger size of peptides, they do not conform to these rules and thus they cannot be used for the design of orally bioavailable cyclic peptides.This project aims to elucidate the physicochemical properties underlying the cell permeability of cyclic peptides. By ascertaining these properties, they can be used as screening filters in mRNA-display based cyclic peptide libraries to efficiently identify cell permeable cyclic peptide hits against target proteins of interest. This has the potential of vastly improving the landscape for cyclic peptide drug development by eliminating the need for modulating cell permeability of hit peptides, which can be highly time-consuming and difficult. Following the generation of these libraries, they can undergo screening against targets for the discovery of cell permeable peptides with therapeutic potential.

市场上的大多数药物都是小分子的。虽然这些药物通常具有良好的口服生物利用度，但小分子药物并不总是对其靶点具有高选择性。这可能导致脱靶效应的毒性增加。同样，小分子不能选择性地靶向具有大结合表面的蛋白质，例如参与蛋白质-蛋白质相互作用的那些蛋白质。大的生物制剂如蛋白质和抗体对这些靶标表现出非常高的选择性，但不是细胞可渗透的，因此只能结合到细胞外蛋白上。此外，与合成分子相比，生物制剂的制造成本很高。肽是有前途的治疗剂，因为它们位于小分子和生物制剂的范围之间，由此它们对其靶标具有高选择性，能够通过靶向具有大结合表面的蛋白质来探测更大的化学空间，并且具有相对低的生产成本。然而，对于肽而言，低细胞渗透性、快速代谢和因此低口服生物利用度的问题仍然存在，并且是其用作治疗剂的主要限制因素。已经观察到肽的环化具有若干结构益处，例如消除N-和C-末端以防止蛋白水解降解，增加刚性和降低极性表面积以改善细胞渗透性和代谢稳定性，已经发现了超过1000种天然存在的环肽，并且一些已经被开发成广泛使用的临床可用药物，例如万古霉素、环孢菌素A和放线菌素D。然而，环肽细胞渗透性的物理化学性质尚不清楚。小分子药物的设计由Lipinski的5法则指导，该法则定义了药物应该具有口服生物利用度的物理化学性质。这样的规则包括分子量<500，logP <5，氢键供体的数量<5和氢键受体的数量<10。由于肽的尺寸较大，它们不符合这些规则，因此它们不能用于设计口服生物可利用的环肽。本项目旨在阐明环肽的细胞渗透性的物理化学性质。通过确定这些性质，它们可以用作基于mRNA展示的环肽文库中的筛选过滤器，以有效地鉴定针对感兴趣的靶蛋白的细胞可渗透的环肽命中。这具有通过消除调节命中肽的细胞渗透性的需要而极大地改善环肽药物开发的前景的潜力，这可能是非常耗时和困难的。在这些文库产生之后，它们可以进行针对靶标的筛选，以发现具有治疗潜力的细胞可渗透肽。